Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
1,319
Views
3
CrossRef citations to date
0
Altmetric
Oncology
Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA
Michael Blankenburga Bayer AG, Berlin, GermanyCorrespondence[email protected]
, Mostafa Elhamamya Bayer AG, Berlin, Germany
, Diana Zhangb Department of Pharmaceuticals, Bayer Healthcare Company Limited, Beijing, China
, Alice Corbinc Wickenstones Ltd., Carlow, Ireland
, Guanyi Jinc Wickenstones Ltd., Carlow, Ireland
, James Harrisc Wickenstones Ltd., Carlow, Ireland
& Gesine Knoblocha Bayer AG, Berlin, Germany
show all
Pages 1015-1029
|
Received 14 Dec 2021, Accepted 03 Aug 2022, Published online: 19 Aug 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.